Global Vaccine Contract Manufacturing Market, By Vaccine Type (Viral Vaccines, Bacterial Vaccines, Recombinant Vaccines, and Toxoid Vaccines), Scale of Operation (Small Scale, Medium Scale, Large Scale), End User (Pharmaceutical Companies, Biotechnology Companies, Academic and Research Institutions Government Agencies and Non-Profit Organizations) - Industry Trends and Forecast to 2031.
Vaccine Contract Manufacturing Market Analysis and Size
The vaccine contract manufacturing market is experiencing rapid growth due to increased demand for vaccines worldwide. Key factors driving this expansion include rising investments in vaccine development, outsourcing of manufacturing processes by pharmaceutical companies, and the need for flexible production capacities. With advancements in biotechnology and regulatory frameworks, the market is expected to continue its upward trajectory, offering lucrative opportunities for contract manufacturers and fostering innovation in vaccine production.
Data Bridge Market Research analyses that the global vaccine contract manufacturing market which was USD 2.82 billion in 2023, is expected to reach USD 5.10 billion by 2031, and is expected to undergo a CAGR of 7.68% during the forecast period 2024 to 2031. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2024 to 2031
|
|
Base Year
|
2023
|
|
Historic Years
|
2022 (Customizable to 2016-2021)
|
|
Quantitative Units
|
Revenue in USD Million, Pricing in USD, Volumes in Units
|
|
Segments Covered
|
Vaccine Type (Viral Vaccines, Bacterial Vaccines, Recombinant Vaccines, and Toxoid Vaccines), Scale of Operation (Small Scale, Medium Scale, Large Scale), End User (Pharmaceutical Companies, Biotechnology Companies, Academic and Research Institutions Government Agencies and Non-Profit Organizations)
|
|
Countries Covered
|
U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, Rest of Middle East and Africa
|
|
Market Players Covered
|
Catalent, Inc. (U.S.), Lonza Group Ltd. (Switzerland), Fujifilm Diosynth Biotechnologies (U.S.), Thermo Fisher Scientific Inc. (U.S.), Samsung Biologics ( South Korea), Emergent BioSolutions Inc. (U.S.), Pfizer CentreOne (U.S.), Grand River Aseptic Manufacturing (GRAM) (U.S.), Albany Molecular Research Inc. (U.S.), Boehringer Ingelheim BioXcellence (Germany)etc.
|
|
Market Opportunities
|
|
Market Definition
Vaccine contract manufacturing refers to the outsourcing of vaccine production to third-party manufacturers known as contract manufacturing organizations (CMOs). Companies or organizations that develop vaccines may choose to collaborate with specialized CMOs to leverage their manufacturing expertise, infrastructure, and capacity. This arrangement allows vaccine developers to focus on research, development, and regulatory activities while relying on CMOs to produce the vaccines on their behalf. Vaccine contract manufacturing enables flexibility, scalability, and cost-effectiveness in vaccine production, particularly during periods of increased demand or when specialized manufacturing capabilities are required.
Vaccine Contract Manufacturing Market Dynamics
Drivers
- Pandemic Preparedness
The COVID-19 pandemic has underscored the critical importance of having robust vaccine manufacturing capacity globally. Governments, pharmaceutical companies, and public health organizations are realizing the necessity of being prepared to respond swiftly and effectively to future pandemics or infectious disease outbreaks. This awareness is driving investments and initiatives to bolster vaccine production capabilities worldwide.
- Technological Advancements
Significant advancements in biotechnology and manufacturing processes are revolutionizing the vaccine production landscape. Innovations such as mRNA technology and novel vaccine platforms offer promising avenues for faster, more scalable, and cost-effective vaccine development and production. These technological breakthroughs are empowering contract manufacturing organizations (CMOs) to offer cutting-edge manufacturing solutions to vaccine developers.
Opportunities
- Increased Demand Creates Opportunities for CMOs
The global demand for vaccines continues to rise due to various factors such as population growth, expanding immunization programs, and the emergence of new infectious diseases. This heightened demand creates opportunities for CMOs to provide flexible and scalable manufacturing services to vaccine developers. By leveraging their expertise and infrastructure, CMOs can play a crucial role in meeting the growing global demand for vaccines.
- Diversification of Portfolio
CMOs have the opportunity to diversify their service offerings beyond traditional vaccines. This includes expanding into specialty vaccines, biologics, and other biological products. By broadening their portfolio, CMOs can cater to a wider range of clients and address emerging needs in the vaccine market. Additionally, venturing into new product categories can enhance the resilience and competitiveness of CMOs in the evolving healthcare landscape.
Restraints/Challenges
- Regulatory Compliance
Vaccine manufacturing is subject to stringent regulatory requirements and quality standards to ensure safety, efficacy, and consistency. Navigating complex regulatory frameworks and obtaining necessary approvals can be a significant challenge for CMOs operating in the vaccine contract manufacturing market. Compliance with regulatory guidelines adds complexity and cost to the manufacturing process, requiring meticulous attention to detail and adherence to best practices.
- Capacity Constraints
One of the primary challenges facing the global vaccine contract manufacturing market is capacity constraints, particularly during times of heightened demand such as pandemics. Scaling up production capacity rapidly while maintaining stringent quality standards poses logistical, operational, and financial challenges for CMOs. Balancing the need for agility and scalability with the imperative of ensuring product quality and safety is a complex task that requires careful planning, investment, and collaboration across the vaccine supply chain.
This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an analyst brief, our team will help you make an informed market decision to achieve market growth.
Recent Developments
- In September 2023, Pfizer and Moderna jointly disclosed that their revised COVID-19 vaccines had gained FDA approval. The objective was to enhance immunity against the most recent variants of the coronavirus and mitigate the anticipated rise in infections during the autumn and winter months in the northern hemisphere
- In September 2023, SK bioscience forged a strategic partnership with Serbia, intending to construct vaccine production facilities within the country as part of their collaboration to develop and manufacture vaccines
Vaccine Contract Manufacturing market Scope
The market is segmented into three notable segments based on vaccine type, scale of operation and end user. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Vaccine Type
- Viral Vaccines
- Bacterial Vaccines
- Recombinant Vaccines
- Toxoid Vaccines
Scale of Operation
- Small Scale
- Medium Scale
- Large Scale
End User
- Pharmaceutical Companies
- Biotechnology Companies
- Academic and Research Institutions
- Government Agencies and Non-Profit Organizations
Vaccine Contract Manufacturing market Regional Analysis/Insights
The market is analysed and market size insights and trends are provided by vaccine type, scale of operation and end user as referenced above.
The countries covered in the market report are U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Brazil, Argentina, rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, and rest of Middle East and Africa
North America dominates the market because of its advanced R&D infrastructure, strong pharmaceutical industry, and access to capital, supportive regulatory environment, market demand, and academic expertise.
Asia-Pacific is expected to witness significant growth during the forecast period of 2024 to 2031 due to rising investments in research and development, expanding pharmaceutical industry, supportive regulatory environment, and increasing demand for advanced drug delivery systems, driving innovation and market expansion in this area.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends, and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs, and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure Growth Installed base and New Technology Penetration
The market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the market. The data is available for historic period 2016-2021.
Competitive Landscape and Vaccine Contract Manufacturing market Share Analysis
The market competitive landscape provides details by competitors. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width, and breadth, application dominance. The above data points provided are only related to the companies' focus related to the market.
Some of the major players operating in the market are:
- Catalent, Inc. (U.S.)
- Lonza Group Ltd. (Switzerland)
- Fujifilm Diosynth Biotechnologies (U.S.)
- Thermo Fisher Scientific Inc. (U.S.)
- Samsung Biologics ( South Korea)
- Emergent BioSolutions Inc. (U.S.)
- Pfizer CentreOne (U.S.)
- Grand River Aseptic Manufacturing (GRAM) (U.S.)
- Albany Molecular Research Inc. (U.S.)
- Boehringer Ingelheim BioXcellence (Germany)
SKU-